ViGenCell Balance Sheet Health
Financial Health criteria checks 5/6
ViGenCell has a total shareholder equity of ₩67.4B and total debt of ₩7.4B, which brings its debt-to-equity ratio to 11%. Its total assets and total liabilities are ₩76.5B and ₩9.0B respectively.
Key information
11.0%
Debt to equity ratio
₩7.40b
Debt
Interest coverage ratio | n/a |
Cash | ₩49.94b |
Equity | ₩67.43b |
Total liabilities | ₩9.02b |
Total assets | ₩76.45b |
Recent financial health updates
No updates
Recent updates
No updates
Financial Position Analysis
Short Term Liabilities: A308080's short term assets (₩51.2B) exceed its short term liabilities (₩8.1B).
Long Term Liabilities: A308080's short term assets (₩51.2B) exceed its long term liabilities (₩961.1M).
Debt to Equity History and Analysis
Debt Level: A308080 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A308080's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A308080 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A308080 has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 19.6% each year.